$599
Abbott Q3 ’24 Earnings; Neurogastrx’s NG101 Reduces GLP-1RA-Related AEs; Kaleido Insulin Pump Receives CE Mark; Alnylam Submits Vutrisiran to EMA
A series of cardiometabolic-related news items have been observed from Abbott, Neurogastrx, ViCentra, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.